Bridge Biotherapeutics, Inc.

Bridge Biotherapeutics, Inc. is a dynamic biotechnology research company dedicated to the discovery and development of innovative therapeutics. With a focus on addressing unmet medical needs, Bridge Biotherapeutics is committed to advancing healthcare solutions in areas such as ulcerative colitis, fibrotic diseases, and cancers.

Headquartered in Seongnam-si, Gyeung-gi do, at 58, Pangyo-ro 255 beon-gil, Bundang-gu, Suite 303, 13486, KR, and with an additional location at One Broadway, 14th Floor, Cambridge, MA 02142, US, Bridge Biotherapeutics operates with a global vision, striving to improve patient outcomes through cutting-edge research and development. Bridge Biotherapeutics is focused on developing BBT-401, a first-in-class Pellino-1 inhibitor for ulcerative colitis, BBT-877, an autotaxin inhibitor for fibrotic diseases including IPF, and BBT-176, a targeted cancer therapy for NSCLC with C797S triple EGFR mutations.

Bridge Biotherapeutics, Inc. is dedicated to innovation and excellence in biotechnology. We invite the management team at Bridge Biotherapeutics to create a customized and exclusive company showcase and product listing on our platform, enhancing their visibility and commercial opportunities.